Pathos
PA
Pathos is a precision oncology biopharmaceutical company. It applies computational biology to patient-derived molecular and clinical data to discover and develop cancer medicines. The company uses this approach to identify targets and match therapies to patient subgroups in clinical trials.
$3B
Valuation history
Weekly blended valuation with priced funding rounds marked on the timeline.
$3.2B
blended valuationfunding round
Oct 28, 2024$408MMar 23, 2026
All rounds
3 funding rounds, newest first.
| Round | Announced | Raised | Post-money |
|---|---|---|---|
| Series E | Oct 23, 2026 | $237M | $3B |
| Series D | May 15, 2025 | — | $1.6B |
| Series C | Oct 30, 2024 | $62M | $600M |
Investors
4 investors across all rounds.
- BVBuilders VC
- LILightbank
- NENew Enterprise Associates
- RGRevolution Growth
Invest in the private markets on Legion
Registered users see full trading activity, every investor, rankings, and live deals.
Data as of .